The NCCN Clinical Practice Guidelines in Oncology® for Ovarian Cancer have been updated and published. These NCCN Guidelines® are now available as Version 1.2010. The NCCN Compendium™ chapters for Ovarian Cancer have also been updated and published as Version 1.2010.
Key updates include the addition of the two following preferred combinations regimens — carboplatin/weekly paclitaxel and carboplatin/liposomal doxorubicin — as cytotoxic therapy for patients with platinum-sensitive epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has recurred.
For complete remission and relapse for both 6 to 12 months and more than 12 months after stopping chemotherapy and clinically low-volume or focal recurrence after a disease-free interval of greater than six months, "consider secondary cytoreductive surgery" was added as a treatment option and a category 1 designation was added to "combination platinum-based chemotherapy preferred for first recurrence."
The NCCN Clinical Practice Guidelines in Oncology® for Palliative Care have also been updated and published. These NCCN Guidelines™ are now available as Version 1.2010.